XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
G
G

Gilead

News

Reuters - 1 week ago

U.S. STOCKS Gold miners, Nikola, Cruise stocks

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Nikola, Cruise stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Chip stocks boosted the Nasdaq on Monday, while the S&P 500 and the Dow edged lower as investors awaited a key inflation reading, commentary from Federal Reserve Chair Jerome Powell and the start of corporate earnings season for monetary policy cues.
C
G
I
J
N
Q
T
U
U
R
S
V
F
M
Reuters - 1 week ago

U.S. STOCKS Ally Financial, Ideaya Biosciences, Brinker

BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Ideaya Biosciences, Brinker Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 hit record highs on Monday, while the Dow scaled a more than one-month high as investors awaited a key inflation report, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of earnings season this week.
B
C
G
I
J
N
Q
T
U
U
H
S
V
F
M
Reuters - 1 week ago

U.S. STOCKS Boeing, Gilead Sciences, Bumble

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Gilead Sciences, Bumble Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were on track for a listless open on Monday, in a week packed with crucial inflation readings, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of the corporate earnings season.
B
G
T
U
H
S
F
Reuters - 1 week ago

Gilead Sciences rises as brokerage upgrades to 'outperform'

BUZZ-Gilead Sciences rises as brokerage upgrades to 'outperform' ** Gilead Sciences' GILD.O shares rise 3.1% to $68.74 premarket ** Brokerage Raymond James raises its rating on company's shares to "outperform" from "market perform" ** Outstanding data from a study of Gilead's long-acting drug lenacapavir in HIV and expected approval of liver diseas
G
Reuters - 2 weeks ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 2 weeks ago

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +6.9% First Solar Inc FSLR.OQ +6.6% Tesla Inc TSLA.OQ +6.5% Vistra Corp VST.N +4.6% NVIDIA Corp NVDA.OQ +4.6% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Constellation Brands Inc
G
N
T
W
U
Reuters - 3 weeks ago

Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle

BRIEF-Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle June 27 (Reuters) - Gilead Sciences Inc GILD.O : CELLARES: KITE, A GILEAD COMPANY, WILL EVALUATE CO'S AUTOMATED MANUFACTURING PLATFORM CELL SHUTTLE Source text for Eikon: ID:nBw10TJNsa Further company coverage: GILD.O
G
Reuters - 3 weeks ago

U.S. stocks weekly: Heat advisory

RPT-BUZZ-U.S. stocks weekly: Heat advisory Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX gains third consecutive week, advances 0.6% .N ** Indeed, benchmark index heating up just as summer solstice hits ** And Nasdaq .IXIC ekes out third-straight weekly gain, though it may be flying on fumes ** Most sectors toasty; Consumer Discretionary and Energy bake most, while Tech and bond-proxies cool off; this, as Growth .IGX was on pace for its best month vs Value .IVX in 24
A
A
G
M
N
U
U
Reuters - 3 weeks ago

U.S. CarMax, Eli Lilly, MicroStrategy

U.S. RESEARCH ROUNDUP-CarMax, Eli Lilly, MicroStrategy June 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CarMax, Eli Lilly and MicroStrategy, on Monday. HIGHLIGHTS * CarMax Inc KMX.N : RBC raises target price to $75 from $73 * Eli Lilly LLY.N : Jefferies raises target price to $1,015 from $994 * MicroStrategy Inc MSTR.O : Canaccord Genuity cuts target price to $1,826 from $2,047 * Sharecare Inc SHCR.O : Canacco
A
A
B
D
G
M
N
V
E
F
T
E
P
R
T
C
C
I
Reuters - 4 weeks ago

U.S. stocks weekly: Heat advisory

BUZZ-U.S. stocks weekly: Heat advisory ** S&P 500 .SPX gains third consecutive week, advances 0.6% .N ** Indeed, benchmark index heating up just as summer solstice hits ** And Nasdaq .IXIC ekes out third-straight weekly gain, though it may be flying on fumes ** Most sectors toasty; Consumer Discretionary and Energy bake most, while Tech and bond-proxies cool off; this, as Growth .IGX was on pace for its best month vs Value .IVX in 24 years, before stumbling relatively last 3 trading days of the
A
A
G
M
N
U
U
Reuters - 4 weeks ago

U.S. STOCKS FactSet, Ryan Specialty, Sarepta

BUZZ-U.S. STOCKS ON THE MOVE-FactSet, Ryan Specialty, Sarepta Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set for a muted open on Friday as chip stocks lost ground, with focus on data from the manufacturing and services sectors for more clues on the health of the world's largest economy.
A
B
C
G
M
N
N
U
U
C
F
Reuters - 4 weeks ago

U.S. STOCKS Apple, Gilead, Spirit Aerosystems

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Gilead, Spirit Aerosystems Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures edged lower on Friday as megacap tech and chip stocks lost ground, with investors awaiting manufacturing and services sectors surveys for more clues on the health of the world's largest economy.
A
B
G
M
N
N
S
R
U
E
C
Reuters - 4 weeks ago

Wall Street set for muted open as investors await business survey data

US STOCKS-Wall Street set for muted open as investors await business survey data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Spirit Aero up following report of Boeing nearing buyout deal Sarepta surges on expanded use of gene therapy Gilead gains after long-acting HIV drug trial success S&P 500 crossed 5,500 points on Thursday Futures down: Dow 0.12%, S&P 500 0.08%, Nasdaq 0.01% Updated at 8:45 a.m.
A
B
G
M
N
Q
U
U
U
Reuters - 4 weeks ago

Gilead set to extend gains on success of long-acting HIV drug trial

BUZZ-Gilead set to extend gains on success of long-acting HIV drug trial Updates ** Shares of drugmaker Gilead Sciences GILD.O rise 3.2% to $70.7 premarket following HIV drug trial success reported on Thursday ** Stock closed 5% higher a day earlier on the news, after rising as much as 8.5% during the session ** Co's late-stage study showed injectable drug lenacapavir was more effective in preventing HIV infection in women versus its existing daily pill Truvada ** There were zero incidents of HI
G
Reuters - 4 weeks ago

Wall Street futures muted ahead of business survey data

US STOCKS-Wall Street futures muted ahead of business survey data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Spirit Aero up following report of Boeing nearing buyout deal Sarepta surges on expanded use of gene therapy Gilead gains after long-acting HIV drug trial success Futures: Dow, S&P 500, Nasdaq flat Updated at 7:29 a.m.
B
G
M
M
N
Q
U
U
U
Reuters - 4 weeks ago

U.S. STOCKS Apple, Gilead, Spirit Aerosystems

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Gilead, Spirit Aerosystems Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures edged lower on Friday as megacap tech and chip stocks lost ground, with investors awaiting manufacturing and services sectors surveys for more clues on the health of the world's largest economy.
A
B
G
M
N
N
R
U
C
Reuters - 4 weeks ago

Wall Street futures edge lower ahead of business survey data

US STOCKS-Wall Street futures edge lower ahead of business survey data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Futures lower: Dow 0.07%, S&P 500 0.15%, Nasdaq 0.12% June 21 (Reuters) - U.S. stock index futures edged lower on Friday as megacap tech and chip stocks lost ground, with investors awaiting manufacturing and services sectors surveys for more clues on the health of the world's largest economy.
A
B
G
M
N
Q
U
U
U
Reuters - 4 weeks ago

Gilead up over long-acting HIV drug trial success

BUZZ-Gilead up over long-acting HIV drug trial success ** Shares of drugmaker Gilead Sciences GILD.O rise 7.3% to $73.5 premarket over Thursday's HIV drug trial success ** Co's late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women versus its existing daily pill Truvada, sending GILD's shar
G
Reuters - 4 weeks ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +8.3% Advanced Micro Devices Inc AMD.OQ +5.2% Sirius XM Holdings Inc SIRI.OQ +3.6% Cognizant Technology Solutions Corp CTSH.OQ +3.5% Workday Inc WDAY.OQ +3.1% Bottom Performers Percent Change Qualcomm Inc QCOM.OQ -5.1% Micron Technology Inc MU.OQ -5.1% Microchip Technology Inc MCHP.OQ -4.5% ON Semiconductor Corp ON.OQ -4.2% Broadcom Inc AVGO.OQ -3.3% Th
B
C
G
M
Q
A
M
O
S
U
W
Reuters - 4 weeks ago

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +8.4% Accenture PLC ACN.N +7.9% Epam Systems Inc EPAM.N +6.3% Salesforce Inc CRM.N +5.1% WestRock Co WRK.N +4.8% Bottom Performers Percent Change Jabil Inc JBL.N -11.2% Enphase Energy Inc ENPH.OQ -8.7% Chipo
C
G
M
Q
S
U
E
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.